Biocon Ltd and Biocon Biologics Ltd Executive Chairperson Kiran Mazumdar-Shaw has been appointed ...
Steady progress in generics/research services * Biocon (BIOS) delivered lower-than-estimated e...
Indian pharmaceuticals giant Biocon registered Rs 3,516 crore revenues for Quarter 1 of FY 2024. ...
Biocon Biologics, a subsidiary of pharmaceutical giant Biocon Ltd, has made several key leadershi...
Biocon Ltd. Buy Biocon Ltd. CMP:253.20, Initiation Range252-254, Stop...
Biocon is currently trading at Rs. 264.20, up by 0.80 points or 0.30% from its previous closing o...
Viatris integration propels numbers; focus on Hulio launch, pending queries.. About ...
Tepid organic growth Biocon Limited’s (Biocon) Q4FY23 performance was boosted ...
* BIOS delivered lower-than-expected 4QFY23 operational performance, led by lower traction in bio...
Biocon is currently trading at Rs. 243.90, up by 1.65 points or 0.68% from its previous closing o...
The Serum Institute of Life Sciences will double its investment in one of Biocon Ltd's units,...
Focus on Viatris integration BIOS’ 3Q results included Viatris consolidation driving 35%...
Global biopharmaceuticals company Biocon Ltd on Tuesday announced its net revenue from operations...
Viatris deal closure: Emergence of an Integrated biosimilar play The completion of USD 3.34bn ...
Biocon is currently trading at Rs. 273.70, up by 4.10 points or 1.52% from its previous closing o...
Biocon is currently trading at Rs. 271.70, up by 0.05 points or 0.02% from its previous closing o...
On the verge of Viatris deal closure Work in progress to strengthen biosimilar pipeline * B...
Vikram Shreekant Kirloskar, an eminent industrialist and Vice-Chairman of Toyota Kirloskar Motors...
Biocon Biologics Ltd, a subsidiary of listed biopharmaceutical company Biocon Ltd, on Tuesday ann...
Biocon is currently trading at Rs. 280.75, up by 0.65 points or 0.23% from its previous closing o...
Multiple headwinds affect earnings Viatris acquisition, Vaccine deal, and potential approvals ...
Biocon is currently trading at Rs. 295.20, up by 2.95 points or 1.01% from its previous closing o...
EBITDA miss; Biosimilar outlook stands positive Biocon has reported 1QFY23 result healthy sale...
Global biopharmaceuticals company Biocon on Wednesday reported 23 per cent rise in revenue for th...
Biocon’s subsidiary -- Biocon Biologics has received EU GMP certificate from the Health Pro...
Biocon is currently trading at Rs. 312.20, up by 1.90 points or 0.61% from its previous closing o...
Biocon is currently trading at Rs. 340.05, up by 17.10 points or 5.29% from its previous closing ...
Generics & research grow; biosimilar stagnates Biocon Limited (Biocon) has reported Q4FY22...
Key News Indian Oil launches methanol-blended petrol on pilot basis in Assam Indian Oil Cor...
The company reported standalone net profit of Rs 38.10 crore for the quarter ended March 31, 2022...
Viatris deal - High risk-reward play with leverage… About the stock: Biocon is a leadin...
Biosimilar deal with Viatris completes the value chain in its Biologics business * BIOS recen...
Viatris deal: Necessary but at a huge cost Biocon Biologics Limited, a subsidiary of Biocon, p...
Biocon is currently trading at Rs. 407.70, up by 7.75 points or 1.94% from its previous closing o...
Strong performance across all segments Biocon Limited is an integrated biopharmaceutical compa...
Q3 witnesses recovery but regulatory hurdles persist Biocon Limited (Biocon) reported better-t...
Biosimilar traction buoys up Q3, momentum to be key About the stock: Biocon mainly operates in...
Biocon is currently trading at Rs. 372.40, up by 8.50 points or 2.34% from its previous closing o...
On course to revive earnings growth We recently met with BIOS’ management to understand ...
Operationally in line with our estimate * Revenue grew 5.5% YoY to INR18.4b (est. INR19.2b) in...
Below is quote on Biocon Q2FY22 number below expectation, stock down 6% by Mr. Yas...
Biocon, the global biopharmaceuticals company of India, on Friday said its Q2FY22 revenue growth ...
Maiden foray into vaccines via Serum alliance… About the stock: Biocon is a leading bio...
Biocon is currently trading at Rs. 369.85, up by 4.70 points or 1.29% from its previous closing o...
Adds Vaccines as a new growth dimension Commercial benefit to kick in from 2HFY23E onwards ...
Key News FDI key to India's aspiration to be a $5 trn economy, says Deloitte CEO Foreig...